Current Update on Preclinical and Clinical Studies of Resveratrol, a Naturally Occurring Phenolic Compound.

Samuel, VP; Gupta, G; Dahiya, R; Jain, DA; Mishra, A; Dua, K

Current Update on Preclinical and Clinical Studies of Resveratrol, a Naturally Occurring Phenolic Compound.

Samuel, VP Gupta, G Dahiya, R Jain, DA Mishra, A Dua, K

Permalink

Publisher:: Begell House
Publication Type:: Journal Article
Citation:: Critical reviews in eukaryotic gene expression, 2019, 29, (6), pp. 529-537
Issue Date:: 2019-01

Closed Access

	Filename	Description	Size
	CRE-27836_29(6)529 537_Resveratrol.pdf	Published version	422.79 kB	Adobe PDF	View/Open

Copyright Clearance Process

Recently Added
In Progress
Closed Access

This item is closed access and not available.

Full metadata record

Field	Value	Language
dc.contributor.author	Samuel, VP
dc.contributor.author	Gupta, G
dc.contributor.author	Dahiya, R
dc.contributor.author	Jain, DA
dc.contributor.author	Mishra, A
dc.contributor.author	Dua, K https://orcid.org/0000-0002-7507-1159
dc.date.accessioned	2020-05-25T05:36:02Z
dc.date.available	2020-05-25T05:36:02Z
dc.date.issued	2019-01
dc.identifier.citation	Critical reviews in eukaryotic gene expression, 2019, 29, (6), pp. 529-537
dc.identifier.issn	1045-4403
dc.identifier.issn	1045-4403
dc.identifier.uri	http://hdl.handle.net/10453/140923
dc.description.abstract	Resveratrol has several therapeutic effects and is a nutraceutical. It was shown to imitate caloric restriction effects, exert anti-inflammatory and antioxidative effects, and affect the development and progression of many diseases through several mechanisms. While there is a wealth of evidence in vitro and in vivo that resveratrol could be a promising therapeutic agent, its potential must be confirmed by preclinical studies and clinical trials. We analyzed the current available preclinical and clinical data on resveratrol's pharmacological action. The bulk of resveratrol's preclinical studies and clinical trials focused on cancer, neurological disorders, cardiovascular diseases, diabetes, nonalcoholic fatty liver disease (NAFLD), and obesity. The latest preclinical studies and clinical trials reported that resveratrol was well tolerated and beneficially influenced biomarkers of disease for neurological disorders, cardiovascular diseases, and diabetes. Nevertheless, in certain types of cancers and in NAFLD, resveratrol had unclear and sometimes even detrimental effects. The major obstacle posed in most preclinical studies and clinical trials was the low bioavailability of resveratrol. This work thus provides useful guidelines for future preclinical and clinical resveratrol study planning and design.
dc.format	Print
dc.language	eng
dc.publisher	Begell House
dc.relation.ispartof	Critical reviews in eukaryotic gene expression
dc.relation.isbasedon	10.1615/critreveukaryotgeneexpr.2019027836
dc.rights	info:eu-repo/semantics/restrictedAccess
dc.subject	0604 Genetics
dc.subject.classification	Biochemistry & Molecular Biology
dc.title	Current Update on Preclinical and Clinical Studies of Resveratrol, a Naturally Occurring Phenolic Compound.
dc.type	Journal Article
utslib.citation.volume	29
utslib.location.activity	United States
utslib.for	0604 Genetics
pubs.organisational-group	/University of Technology Sydney/Graduate School of Health
pubs.organisational-group	/University of Technology Sydney
utslib.copyright.status	closed_access	*
pubs.consider-herdc	false
dc.date.updated	2020-05-25T05:35:59Z
pubs.issue	6
pubs.publication-status	Published
pubs.volume	29
utslib.start-page	529
utslib.citation.issue	6

Abstract:

Resveratrol has several therapeutic effects and is a nutraceutical. It was shown to imitate caloric restriction effects, exert anti-inflammatory and antioxidative effects, and affect the development and progression of many diseases through several mechanisms. While there is a wealth of evidence in vitro and in vivo that resveratrol could be a promising therapeutic agent, its potential must be confirmed by preclinical studies and clinical trials. We analyzed the current available preclinical and clinical data on resveratrol's pharmacological action. The bulk of resveratrol's preclinical studies and clinical trials focused on cancer, neurological disorders, cardiovascular diseases, diabetes, nonalcoholic fatty liver disease (NAFLD), and obesity. The latest preclinical studies and clinical trials reported that resveratrol was well tolerated and beneficially influenced biomarkers of disease for neurological disorders, cardiovascular diseases, and diabetes. Nevertheless, in certain types of cancers and in NAFLD, resveratrol had unclear and sometimes even detrimental effects. The major obstacle posed in most preclinical studies and clinical trials was the low bioavailability of resveratrol. This work thus provides useful guidelines for future preclinical and clinical resveratrol study planning and design.

Please use this identifier to cite or link to this item:

http://hdl.handle.net/10453/140923